Concentrations of Levofloxacin, Ofloxacin, and Ciprofloxacin in Human Corneal Stromal Tissue and Aqueous Humor after Topical Administration

Cornea

Volumn 23, Issue 3, 2004, Pages 255-263

  Healy, Daniel P ^b   Holland, Edward J ^a,b   Nordlund, Michael L ^a,b   Dunn, Steven ^c   Chow, Christopher ^c   Lindstrom, Richard L ^d   Hardten, David ^d   Davis, Elizabeth ^d  

^a CINCINNATI EYE INSTITUTE   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c Michigan Cornea Consultants   (United States)

^d MINNESOTA EYE CONSULTANTS   (United States)

Author keywords

Aqueous humor; Ciprofloxacin; Cornea; Fluoroquinolones; Levofloxacin; Ofloxacin

Indexed keywords

CEFAZOLIN; CEFTAZIDIME; CEFUROXIME; CIPROFLOXACIN; EYE DROPS; GENTAMICIN; LEVOFLOXACIN; NORFLOXACIN; OFLOXACIN; PIPERACILLIN; TOBRAMYCIN;

AQUEOUS HUMOR; ARTICLE; CLINICAL TRIAL; CONGENITAL CORNEA DYSTROPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA STROMA; DOUBLE BLIND PROCEDURE; DRUG PENETRATION; DRUG TOLERABILITY; EXCISION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; KERATITIS; KERATOCONUS; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; PARACENTESIS; PENETRATING KERATOPLASTY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

ADMINISTRATION, TOPICAL; ADULT; ANTI-INFECTIVE AGENTS; AQUEOUS HUMOR; CIPROFLOXACIN; CORNEAL STROMA; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KERATOPLASTY, PENETRATING; MALE; OFLOXACIN; OPHTHALMIC SOLUTIONS; PROSPECTIVE STUDIES;

EID: 1642545588     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003226-200404000-00007     Document Type: Article

References (33)

1. Baum J. Infections of the eye. Clin Infect Dis. 1995;21:479-488.
2. th ed. Philadelphia: Churchill Livingstone, 2000:1257-1266.
3. Robert P-Y, Adenis J-P. Comparative review of topical ophthalmic antibacterial preparations. Drugs. 2001;61:175-185.
4. Smith A, Pennefather PM, Kaye SB, et al. Fluoroquinolones place in ocular therapy. Drugs. 2001;61:746-761.
5. O'Brien TP, Maguire MG, Fink NE, et al and the Bacterial Keratitis Study Research Group. Efficacy of ofloxacin vs cefazolin and tobramycin in the therapy for bacterial keratitis. Arch Ophthalmol. 1995;113:1257-1265.
6. Gangopadhyay N, Daniell M, Weih L, et al. Fluoroquinolones and fortified antibiotics for treating bacterial corneal ulcers. Br J Ophthalmol. 2000;84:378-384.
7. The Ofloxacin Study Group. Ofloxacin monotherapy for the primary treatment of microbial keratitis. A double-masked, randomized, controlled trial with conventional dual therapy. Ophthalmology. 1997;104:1902-1909.
8. Hyndiuk RA, Eiferman RA, Caldwell DR, et al. (The ciprofloxacin bacterial keratitis study group). Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers. Ophthalmology. 1996;103:1854-1863.
9. Panda A, Ahuja R, Sastry SS. Comparison of topical 0.3% ofloxacin with fortified tobramycin plus cefazolin in the treatment of bacterial keratitis. Eye. 1999;13:744-747.
10. Prajna NV, George C, Selvaraj S, et al. Bacteriologic and clinical efficacy of ofloxacin 0.3% versus ciprofloxacin 0.3% ophthalmic solutions in the treatment of patients with culture-positive bacterial keratitis. Cornea. 2001;20:175-178.
11. Ross D, Riley CM. Aqueous solubilities of some variously substituted quinolone antimicrobials. Int J Pharmaceutics. 1990;63:237-250.
12. Mitsui Y, Ooishi M, Sasaki K, et al. AQCmax as a pharmacokinetic parameter of ophthalmic solution. J Eye. 1995;12:783-786.
13. Donnenfeld ED, Schrier A, Perry HD, et al. Penetration of topically applied ciprofloxacin, norfloxacin, and ofloxacin into the aqueous humor. Ophthalmology. 1994;101:902-905.
14. Diamond JP, White L, Leeming JP, et al. Topical 0.3% ciprofloxacin, norfloxacin, and ofloxacin in treatment of bacterial keratitis: a new method for comparative evaluation of ocular drug penetration. Br J Ophthalmol. 1995;79:606-609.
15. von Keyserlingk J, Beck R, Fischer U, et al. Penetration of ciprofloxacin, norfloxacin and ofloxacin into the aqueous humour of patients by different topical application modes. Eur J Clin Pharmacol. 1997;53:251-255.
16. Çekiç O, Batman C, Totan Y, et al. Penetration of ofloxacin and ciprofloxacin in aqueous humor after topical administration. Ophthalmic Surg Lasers. 1999;30:465-468.
17. Morrissey I, Hoshino K, Sato K, et al. Mechanism of differential activities of ofloxacin enantiomers. Antimicrob Agents Chemother. 1996;40:1775-1784.
18. Kawazu K, Midori Y, Shiono H, et al. Characterization of the carrier-mediated transport of levofloxacin, a fluoroquinolone antimicrobial agent, in rabbit cornea. J Pharm Pharmacol. 1999;51:797-801.
19. Kawazu K, Midori Y, Ota A. Cultured rabbit corneal epithelium elicits levofloxacin absorption and secretion. J Pharm Pharmacol. 1999;51:797-801.
20. Price FW Jr, Whitson WE, Collins KS, et al. Corneal tissue levels of topically applied ciprofloxacin. Cornea. 1995;14:152-156.
21. Liang H, Kays MB, Sowinski KM. Separation of levofloxacin, ciprofloxacin, gatifloxacin, moxifloxacin, trovafloxacin, and cinoxacin by high-performance liquid chromatography: application to levofloxacin determination in human plasma. J Chromatogr B. 2002;772:53-63.
22. McDermott ML, Tran TD, Cowden JW, et al. Corneal stromal penetration of topical ciprofloxacin in humans. Ophthalmology. 1993;100:197-200.
23. Huber-Spitzy VN, Czejka M, Georgiew L, et al. Penetration of norfloxacin into the aqueous humor of the human eye. Invest Ophthalmol Vis Sci. 1992;33:1723-1726.
24. Bouchard CS, King KK, Holmes JM. The kinetics of anterior chamber ofloxacin penetration. Cornea. 1996;15:72-75.
25. Price FW Jr, Whitson WE, Gonzales J, et al. Corneal tissue levels of topically applied ofloxacin. J Cataract Refract Surg. 1997;23:898-902.
26. Donnenfeld ED, Perry HD, Snyder RW, et al. Intracorneal, aqueous humor, and vitreous humor penetration of topical and oral ofloxacin. Arch Ophthalmol. 1997;115:173-176.
27. Çekiç O, Batman C, Yasar Ü, et al. Human aqueous and vitreous humour levels of ciprofloxacin following oral and topical administration. Eye. 1999;13:555-558.
28. Leeming JP, Diamond JP, Triss R, et al. Ocular penetration of topical ciprofloxacin and norfloxacin drops and their effect upon eyelid flora. Br J Ophthamol. 1994;78:546-548.
29. Ishikawa K, Yamada M, Mochizuki H, Kawai M, Mashima Y. Corneal stromal penetration of topically applied levofloxacin, norfloxacin, and lomefloxacin in the same human eyes. Presented at annual ARVO meeting, Ft Lauderdale, FL, May 2002, abstract 1578.
30. Wimer SM, Schoonover L, Garrison MW. Levofloxacin: a therapeutic review. Clin Therapeutics. 1998;20:1049-1070.
31. Callegan MC, Booth MC, Gilmore MS. In vitro pharmacodynamics of ofloxacin and ciprofloxacin against common ocular pathogens. Cornea. 2000;19:539-545.
32. Graves A, Henry M, O'Brien TP, et al. In vitro susceptibilities of bacterial ocular isolates to fluoroquinolones. Cornea. 2001;20:301-305.
33. Jensen HG, Felix C. The In Vitro Antibiotic Testing Group. In vitro antibiotic susceptibilities of ocular isolates in North and South America. Cornea. 1998;17:79-87.